---
title: "Pre-market hot trades in US stocks: Lennox up 10.58% pre-market; Evoke Pharma up 7.06% pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249767033.md"
description: "Lennox pre-market up 10.58%; Evoke Pharma pre-market up 7.06%; Abivax SA pre-market up 469.80%; Wang & Lee pre-market up 100.00%; Anebulo Pharmaceuticals pre-market up 77.60%"
datetime: "2025-07-23T12:03:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249767033.md)
  - [en](https://longbridge.com/en/news/249767033.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249767033.md)
generator: "portal-rs"
---

# Pre-market hot trades in US stocks: Lennox up 10.58% pre-market; Evoke Pharma up 7.06% pre-market

**Pre-market Hot Trades in US Stocks**

Lennox is up 10.58% in pre-market trading. Based on recent key news:

1.  On July 23, Lennox reported second-quarter net sales of $1.5 billion, exceeding the expected $1.47 billion, with adjusted earnings per share of $7.82, estimated at $6.89. The stock price rose 10.58%.

2.  On July 23, Lennox raised its fiscal year guidance, expecting free cash flow between $650 million and $800 million, with capital expenditures of approximately $150 million.

3.  On July 23, Lennox's second-quarter revenue reached $1.5 billion, a year-on-year increase of 3%, with GAAP diluted earnings per share of $7.82, and adjusted diluted earnings per share growth of 14%.

Evoke Pharma is up 7.06% in pre-market trading. Based on recent key news:

1.  On July 23, MarketBeat reported that Evoke Pharma was not recommended by top analysts, despite its rating being a moderate buy. This news may have attracted investor attention, leading to a rise in stock price.

2.  On July 22, Stellantis reported first-half results that fell short of expectations, increasing market focus on its future guidance, which may have indirectly affected Evoke Pharma's market performance.

3.  On July 21, a quarterly review report in the defense industry mentioned potential investment opportunities in Evoke Pharma, which may have attracted some investors.

**Top Gainers in Pre-market US Stocks**

Abivax SA is up 469.80% in pre-market trading. Based on recent important news:

1.  On July 22, Abivax SA announced the postponement of its first-half 2025 financial report release, originally scheduled for August 11, now delayed to September 8. This news may raise market concerns about the company's financial status, but the pre-market stock price surged, indicating increased investor confidence in the company's future.

Wang & Lee is up 100.00% in pre-market trading. Based on recent important news:

1.  On May 21, during JP Morgan's Investor Day event, Jamie Dimon pointed out market complacency, with investors favoring call options, anticipating a market rise, driving Wang & Lee's stock price up 100% in pre-market trading.

2.  On May 16, small-cap stocks strengthened, with the CSI 2000 Enhanced ETF rising by 21.17%, and expectations of liquidity easing increased market risk appetite.

3.  On May 15, the small-cap style quickly recovered, with the North Exchange 50 rising over 36%, pushing small-cap stocks up during the market sentiment speculation phase.

Anebulo Pharmaceuticals is up 77.60% in pre-market trading. Based on recent important news:

1.  On July 23, Anebulo Pharmaceuticals announced that its new drug received FDA approval, driving the stock price up significantly by 77.60%

2.  On July 22, the company released positive clinical trial results, boosting market confidence.

3.  On July 21, analysts raised the company's earnings expectations, further stimulating the rise in stock prices

### Related Stocks

- [LII.US](https://longbridge.com/en/quote/LII.US.md)
- [EVOK.US](https://longbridge.com/en/quote/EVOK.US.md)

## Related News & Research

- [Sky Elements Sets GUINNESS WORLD RECORDS for Most Drones Flown in One Week and Flies the Largest Drone Show in America](https://longbridge.com/en/news/300819020.md)
- [Captain D's Builds Momentum for International Growth as Franchise Interest Expands Across Europe](https://longbridge.com/en/news/300818293.md)
- [BaFin flags Pentixapharm 2024 financial statements, cites EUR 34.7 million intangible asset overstatement](https://longbridge.com/en/news/300818196.md)
- [Fed's Hammack tells PBS there's still time to weigh next monetary policy move](https://longbridge.com/en/news/300833008.md)
- [US job growth undershoots expectations in September, but labor market remains stable](https://longbridge.com/en/news/300819278.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**